Wedbush Maintains Neutral on Abivax, Raises Price Target to $110

Benzinga Newsdesk www.benzinga.com Neutral 54.6%

Neg 0% Neu 54.6% Pos 0%

Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and raises the price target from $90 to $110.